A recent study of Arizona’s bioscience sector showed high marks for the progress made since the launch of the state’s strategic roadmap outlined in 2002 in support of its innovation ecosystem.
Arizona’s bioscience sector continues to set a national example for how focused, long-term strategy can elevate an innovation ecosystem. According to a new analysis by TEConomy Partners, released in conjunction with the Flinn Foundation’s Arizona Bioscience Roadmap, the state is posting record highs in research funding and showing increased competitiveness across multiple key metrics in bioscience.
This milestone report—based on over two decades of strategic effort since the launch of the Bioscience Roadmap in 2002—paints a compelling picture: Arizona is not only participating in the nation’s bioscience boom but also beginning to lead in important areas of growth.
Record Research Funding, National Competitiveness
Among the most striking achievements is Arizona’s new record of $368 million in annual National Institutes of Health (NIH) grant funding for 2024. This is a growth rate four times the national average between 2020 and 2024, underscoring the state’s rapidly advancing stature in biomedical research. Arizona’s share of national NIH funding has climbed to 0.99%, just shy of the 1% benchmark that has long been a symbolic target.
This increase is more than statistical—it reflects a robust research infrastructure anchored by major universities such as Arizona State University, the University of Arizona, and Northern Arizona University. Together, these institutions pushed bioscience-related R&D spending to more than $800 million in 2023, a record high. With a growth rate of 30%, Arizona’s academic research funding far outpaces the national average of 25%, marking it as a hotbed for cutting-edge science and innovation.
“Arizona’s research community continues to play a vital role in the overall growth of the state’s bioscience sector and innovation ecosystem,” said Ryan Helwig, principal and senior director at TEConomy Partners. “This is a clear sign of competitiveness that aligns with a long-term strategic vision.”
Job Growth Outpaces the Nation
Economic impact is another area where Arizona is flexing its strength. From 2020 to 2023, the bioscience sector’s job growth in the state reached 8.1%, compared to the national average of 6.7%. Even more impressive, non-hospital bioscience jobs—spanning biotech firms, R&D labs, and manufacturing—rose by a staggering 19%, with about 40,000 people now employed in those roles.
Not only are there more jobs, but they’re paying well. The average annual wage for bioscience workers in 2023 was $87,000—roughly $20,000 above the state’s private-sector average. This wage growth, which matched the national pace of 15%, reflects the high value and advanced skill sets associated with bioscience work.
Startup Formation and Venture Capital Activity
Arizona’s bioscience innovation engine is also being powered by its universities and startup community. In 2024, 14 bioscience startups were spun out of the state’s research universities, a modest increase over the previous year but still below 2021’s peak of 27. These startups are integral to translating scientific discoveries into market-ready innovations, a process vital to commercialization and long-term economic sustainability.
Venture capital activity, though mirroring a national downtrend, remained relatively strong in 2024. Arizona bioscience firms secured $289 million across 50 deals—the highest total since 2021. While deal count has decreased from its peak of 71 in 2021, the sustained capital inflow highlights investor confidence in the Arizona innovation ecosystem.
“Arizona’s bioscience sector is on a roll,” said Dr. Tammy McLeod, president and CEO of the Flinn Foundation. “With world-class talent across research, entrepreneurship, education, and health care, we are confident that Arizona will have improved health outcomes and quality of life for years to come.”
Building on Momentum with a New Roadmap
The Flinn Foundation’s Bioscience Roadmap has long been a guiding force for Arizona’s progress, and its conclusion marks a transition to a new phase. To chart the next chapter, the Foundation has commissioned SRI International to draft a new plan set to launch in the fall of 2025. This new strategic framework will build on Arizona’s existing strengths while addressing areas for improvement—particularly in commercialization and startup acceleration.
The initiative remains under the stewardship of the Arizona Bioscience Roadmap Steering Committee, a coalition that includes leaders from business, academia, healthcare, and government. Their continued guidance ensures that the state’s efforts remain both collaborative and actionable.
The Broader Innovation Ecosystem
Arizona’s bioscience achievements are not happening in a vacuum. They are part of a broader state innovation ecosystem that spans technology, clean energy, advanced manufacturing, and health tech. Organizations like the Arizona Commerce Authority and incubators such as the Center for Entrepreneurial Innovation (CEI) and the University of Arizona’s Forge are playing vital roles in connecting bioscience startups with resources, talent, and market access.
This convergence of academia, capital, talent, and policy is transforming Arizona into a national hub for life sciences innovation. With a favorable business climate, fast-growing population, and rising educational attainment levels, the state is well-positioned to continue attracting top-tier talent and investment.
The Future
As Arizona prepares to unveil its next strategic bioscience roadmap, the foundation has been laid for another decade of growth, innovation, and impact. Whether in research funding, job creation, startup activity, or national competitiveness, the data reveals a state that is not only keeping pace—but setting the pace—for bioscience innovation in the United States.
For those looking to invest, collaborate, or innovate in the biosciences, Arizona’s ecosystem presents a compelling opportunity—fueled by vision, powered by talent, and sustained by an unwavering commitment to scientific progress and economic vitality.
